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remained otherwise well until January, 1996, when he
developed recurrent biliary stricturing with jaundice and
worsening diarrhoea. Trough cyclosporin concentrations
were considered sub-therapeutic at 60 ng/mL and so he was
converted to Neoral therapy at the same dose. Several 12-h
trough whole blood cyclosporin levels were taken over the
following 2 months, and did not exceed 125 ng/mL. In
March, 1996, he complained of altered colour perception,
which improved after empirical parenteral vitamin A therapy.
In April, 1996, he was admitted with coma following recent
onset of myalgia and dysarthria. On arrival he was
unresponsive, restless, and hyperventilating with decorticate
movements, extensor plantar responses, and bilateral ankle
clonus. Investigations revealed metabolic acidosis and renal
impairment; arterial pH 7·1, bicarbonate 8·4 mmol/L, serum
creatinine 279 µmol/L (rising from 148 µmol/L 4 weeks
previously). Serum sodium level was 135 mmol/L.
Cyclosporin level was 52 ng/mL. An electroencephalogram
and cerebrospinal fluid examination were normal.
Computed tomography and magnetic resonance imaging
showed white matter changes consistent with
leucoencephalopathy (figure), which had progressed
substantially since 1993. He was mechanically ventilated and
treated with empirical antimicrobial therapy. Cyclosporin
and azathioprine were discontinued. He failed to regain
consciousness after withdrawal of sedation and died 20 days
after presentation. A screen for viruses taken before death,
including PCR analysis of cerebrospinal fluid for JC virus,
was negative. Necropsy of the brain revealed axonal
degeneration in the areas of white matter abnormality seen
on the scans, with associated oedema, scattered
lymphocytes, and macrophages localised to the white matter.
This case has clinical, radiological, and pathological
features consistent with leucoencephalopathy, a rare
condition previously described in patients treated with
cyclosporin or tacrolimus.1,3 However, most previously
described leucoencephalopathies associated with
immunosuppression occurred early during therapy and were
reversible with good recovery. Unusual features in this case
included late onset (3 years after starting
immunosuppressive therapy), more extensive and fronto-
parietal distribution of white matter changes, and
deterioration despite withdrawal of cyclosporin, all
suggesting an extreme variant of the disease. Neurotoxic
side-effects of cyclosporin are more frequently reported in
liver transplant recipients than in other organ recipients,
which may reflect increased permeability of the blood-brain
barrier consequent upon liver failure.1,3,4 Other risk factors
include high trough cyclosporin concentrations, and low
serum cholesterol levels, although a causative effect of the
latter is not proven. Neoral, the recently introduced
microemulsion formulation of cyclosporin, is more
bioavailable than Sandimmun. Patients with liver or gut
impairment who are poor absorbers of Sandimmun may be
particularly predisposed to increases in peak cyclosporin
concentrations when converted to Neoral.5 Our patient had a
combination of metabolic derangements that can predispose
to encephalopathy, including renal and hepatic impairment
and probable bicarbonate deficiency from chronic diarrhoea.
Although there was no proof that alteration in his
immunosuppressive therapy led to his illness, the increased
bioavailability of Neoral with high peak blood concentrations
could have contributed to the development of
leucoencephalopathy. Alternatively, this may have been
precipitated by worsening metabolic derangement in a
predisposed individual. In either case, this report suggests
the need for caution when considering alteration of
immunosuppressive therapy in patients with intercurrent
liver or other metabolic disease, with vigilant observation for
neurological side-effects.
We are grateful to Sandoz (UK) Ltd for helpful discussion.
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Multidrug resistance protein in
recurrent breast cancer
Kees Nooter, Guy Brutel de la Riviere, Jan Klijn, Gerrit Stoter,
John Foekens
Lack of response to anticancer chemotherapy is one of the
main problems in recurrent breast cancer, but the
mechanisms underlying this drug resistance are unclear. We
studied the expression of multidrug resistance protein
(MRP)1 in biopsy specimens from 64 primary tumours in
patients with operable breast cancer who showed recurrent
disease and were treated with chemotherapy as first-line
treatment or after showing no response to endocrine therapy.
We then related MRP immunoreactivity to patient and
tumour characteristics, and treatment outcome. MRP
expression was analysed with the MRP-specific  monoclonal
antibody MRPr12 as described previously.3 Staining of
tumour cells was scored as negative (weak staining of
stromal cells), or positive (weak to strong cytoplasmic and
membranous staining).
MRP expression in the primary tumour was positive in
eight (35%) of the 23 patients who received first-line
chemotherapy for recurrent disease and in 12 (29%) of the
41 patients who received chemotherapy after non-response
to one or more hormonal treatments. Of the 23 patients
receiving first-line chemotherapy, 11 (48%) responded
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(seven partial or complete responses, four stable disease for
more than 6 months), while 12 (52%) did not. The median
time to progression for responding patients was 11 months
(range 5–29) and for non-responding patients 3 months
(range 0–6).The rate of response did not depend on the type
of chemotherapy given. There was no difference between
responders and non-responders in age, lymph node status, or
recurrence-free period. Two of eight (25%) postmenopausal
patients responded, compared with nine of 15 (60%)
premenopausal patients. The incidence of MRP-positive
tumours was not different for patients with soft tissue (one
of three), bone (two of eight), or visceral metastases (five of
twelve) as predominant site of relapse. In patients receiving
first-line chemotherapy, MRP was more often positive in
non-responding tumours (50%) than in responding tumours
(18%). Only one of eight (13%) MRP-positive tumours had
an objective response (5 months), compared with six of 15
(40%) MRP-negative tumours. Analysing for overall
response, including stable disease, two of eight (25%) MRP-
positive tumours responded, compared with nine of 15
(60%) MRP-negative tumours (odds ratio: 0·22; 95% CI
0·03–1·49). Patients with MRP-positive tumours showed a
shorter time to progression on first-line chemotherapy than
those with MRP-negative tumours (Cox proportional hazard
model, p=0·006, figure). The relative hazard rate for time to
progression in patients with MRP-positive tumours,
compared with MRP-negative tumours, was 4·08 (95% CI
1·50–11·12). At 9 months, all eight patients with MRP-
positive tumours showed disease progression, while seven of
15 of those with MRP-negative tumours did not (four
objective responses, three stable disease). In Cox
multivariate analysis for time to progression, MRP was the
only significant variable in the model.
Of the 41 patients who received chemotherapy after one
or more lines of hormonal therapy, 19 (46%) responded
(seven partial responses, 12 stable disease), whereas 22
(54%) did not. In these patients, there was no significant
difference in the rate or duration of response, or in the time
to progression between patients with MRP-positive and
MRP-negative tumours, suggesting differences in tumour
cell biology. Metastatic breast cancer patients who receive
chemotherapy as the first choice of treatment usually are
premenopausal, are oestrogen-receptor and progesterone-
receptor negative, and may have visceral metastases. These
are all unfavourable prognostic factors. Women first treated
with hormonal therapy are usually postmenopausal, have
receptor positive tumours, and have bone rather than visceral
metastases. We conclude that MRP expression is an
important predictor of poor prognosis in patients with breast
cancer who were treated with chemotherapy as first-line
systemic therapy for recurrence.
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Complement C3 and factor B
cerebrospinal fluid concentrations in
bacterial and aseptic meningitis
Philip F Stahel, David Nadal, Hans-Walter Pfister,
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Establishing a diagnosis is difficult in most cases of acute
meningitis, since its clinical signs are non-specific, and
laboratory examination of cerebrospinal fluid (CSF) often
does not accurately differentiate between bacterial and
aseptic meningitis.1,2 Therefore the identification of a
discriminating parameter, which might lead to a rapid and
accurate clinical test, would be of value in the differential
diagnosis of acute meningitis.
Several studies have suggested that the complement system
contributes to intrathecal inflammation in bacterial
meningitis.3 In a retrospective analysis, we measured the
concentrations of the alternative pathway complement
components C3 and factor B in CSF samples obtained by
lumbar puncture from 39 patients with clinically suspected
acute infectious meningitis, and from 64 controls without
central nervous system infection, with an ELISA developed in
our laboratory. 18 patients (median age 40 years; range
14–67 years; 9 female) were diagnosed as having bacterial
meningitis, on the basis of positive bacterial culture or on
detection of bacterial antigen in CSF. The pathogens were
Streptococcus pneumoniae (n=10), Haemophilus influenzae (3),
Neisseria meningitidis (3), Listeria monocytogenes (1), and
Streptococcus bovis (1). 21 patients were diagnosed as having
aseptic meningitis (median age 8 years; range 2 months to 13
years; 6 female) on the basis of CSF pleocytosis with a
predominance of mononuclear cells, negative bacterial and
fungal CSF and blood cultures, negative results on CSF
antigen detection tests for S pneumoniae, H influenzae, and
N meningitidis, and full recovery without antibiotic treatment.
No patient had received antibiotics or steroids before
diagnostic lumbar puncture, and all CSF samples were
obtained on admission. The mean C3 concentration in the
CSF of patients with bacterial meningitis (48·32 [SD 50·74]
µg/mL) was significantly higher than in aseptic meningitis
(2·16 [1·82] µg/mL; p<0·001, Wilcoxon rank sum test) or in
controls (2·49 [2·18] µg/mL; p<0·001). Similarly, factor B
CSF concentrations were significantly raised in patients with
bacterial meningitis (15·89 [17·36] µg/mL) compared with
those with aseptic meningitis (0·25 [0·20] µg/mL; p<0·001)
or controls (0·29 [0·26] µg/mL; p<0·001). C3 and factor B
CSF concentrations in bacterial meningitis did not correlate
